Biodexa Pharmaceuticals Plc, a public limited company organized under the laws of England and Wales, has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, raised a total of $6,793,406 USD. The date of the first sale was reported as December 21, 2023, and the offering was completed without any remaining securities to be sold. Biodexa Pharmaceuticals, with its principal place of business in Cardiff, United Kingdom, has declined to disclose its revenue range or aggregate net asset value. The securities offered included equity, options, warrants, or other rights to acquire another security, and...Show More

Biodexa Pharmaceuticals Plc, a public limited company organized under the laws of England and Wales, has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which was not subject to review by the SEC for accuracy, raised a total of $6,793,406 USD. The date of the first sale was reported as December 21, 2023, and the offering was completed without any remaining securities to be sold. Biodexa Pharmaceuticals, with its principal place of business in Cardiff, United Kingdom, has declined to disclose its revenue range or aggregate net asset value. The securities offered included equity, options, warrants, or other rights to acquire another security, and securities to be acquired upon the exercise of options, warrants, or other rights. The company's executive officers and directors, including CEO and CFO Stephen Stamp, were named in the filing. The offering did not involve any sales compensation such as broker or dealer commissions or finders' fees, and the proceeds will not be used for payments to any executive officers, directors, or promoters. Biodexa Pharmaceuticals has claimed an exemption under Rule 506(b) of the Securities Act and has confirmed that the offering will not last more than one year.